人参皂苷Rb2对高脂性脂肪肝小鼠肝脏脂质代谢的影响及其机制

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (1336 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the role of ginsenoside Rb2 in hepatic lipid metabolism in fatty liver mice and its mechanism. Methods: Male C57BL/6J mice were randomly divided into normal control group, high-fat model group and ginsenoside Rb2 group. The normal control group was fed with 10% kcal control diet, and the rest was fed with 60% kcal high fat diet for 8 weeks. PBS or ginsenoside Rb2 (40 mg•kg-1•d-1) was injected intraperitoneally for 10 days. Realtime PCR and Western blot were used to investigate the expression and mechanism of lipid metabolism-related genes such as lipid synthesis and fatty acid oxidation in liver tissues. Results: Ginsenoside Rb2 significantly reduced liver weight, improved hepatic steatosis, down-regulated fatty acid synthase (FAS), lipoprotein lipase (LPL), sterol regulatory element binding protein (SREBP)-1c, and up-regulated carnitine palmitoyl transferase (CPT)-1 and cholesterol 7α-hydroxylase (CYP7A1) mRNA levels, increased the expression of hepatic peroxisome proliferator-activated receptor (PPAR) alpha gene and protein. Conclusion: Ginsenoside Rb2 can attenuate hyperlipidemic fatty liver, and its mechanism may be related to the increase of PPARα expression in the liver and the regulation of target genes expression such as SREBP-1c, FAS and CYP7A1 related to lipid metabolism.

Key words： ginsenoside Rb2 hyperlipidemic fatty liver peroxisome proliferator-activated receptor α hepatic steatosis

Received: 07 December 2017

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HONG Yilian
	GU Xuejiang
	XU Jing
	LIN Yi
	SI Qiya.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I5/338

[1] BERNSTEIN D E. Nonalcoholic fatty liver disease: An expanding health care epidemic[J]. Clin Liver Dis, 2018, 22 (1): 13-14.
[2] 娄林洁, 游艳婷, 马柯, 等. 香砂六君丸对非酒精性脂肪肝大鼠肝脏线粒体的影响[J]. 温州医科大学学报, 2017, 47 (11): 796-800.
[3] MUSSO G, CASSADER M, GAMBINO R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies[J]. Nat Rev Drug Discov, 2016, 15(4): 249-274.
[4] LI Z, JI G E. Ginseng and obesity[J]. J Ginseng Res, 2018, 42(1): 1-8.
[5] Park T Y, Hong M, Sung H, et al. Effect of Korean Red Ginseng in chronic liver disease[J]. J Ginseng Res, 2017, 41(4): 450-455.
[6] LEE J B, YOON S J, LEE S H, et al. Ginsenoside Rg3 ameliorated HFD-induced hepatic steatosis through downregulation of STAT5-PPARgamma[J]. J Endocrinol, 2017, 235(3): 223-235.
[7] XIAO N, LOU M D, LU Y T, et al. Ginsenoside Rg5 attenuates hepatic glucagon response via suppression of succinate-associated HIF-1alpha induction in HFD-fed mice[J]. Diabetologia, 2017, 60(6): 1084-1093.
[8] YU X, YE L, ZHANG H, et al. Ginsenoside Rb1 ameliorates liver fat accumulation by upregulating perilipin expression in adipose tissue of db/db obese mice[J]. J Ginseng Res, 2015, 39(3): 199-205.
[9] SHEN L, XIONG Y, WANG D Q, et al. Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats[J]. J Lipid Res, 2013, 54(5): 1430-1438.
[10] HUANG Q, WANG T, YANG L, et al. Ginsenoside Rb2 alleviates hepatic lipid accumulation by restoring autophagy via induction of Sirt1 and activation of AMPK[J]. Int J Mol Sci, 2017, 18(5): 1063-1064.
[11] UNGER R H, ORCI L. Diseases of liporegulation: new perspective on obesity and related disorders[J]. FASEB J, 2001, 15(2): 312-321.
[12] BASANTANI M K, SITNICK M T, CAI L, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome[J]. J Lipid Res, 2011, 52(2): 318-329.
[13] ARENDT B M, COMELLI E M, MA D W, et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids[J]. Hepatology, 2015, 61(5): 1565-1578.
[14] YAN D, LEHTO M, RASILAINEN L, et al. Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis[J]. Arterioscler Thromb Vasc Biol, 2007, 27(5): 1108-1114.
[15] ZHALDAK D A, MELEKHOVETS O K, ORLOVSKYI V F. CYP7A1 gene polymorphism and the characteristics of dyslipidemias in patients with nonalcoholic fatty liver disease concurrent with hypothyroidism[J]. Ter Arkh, 2017, 89 (10): 62-65.
[16] LI Q, HONG J, WU J, et al. The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: a meta-analysis[J]. J Clin Lipidol, 2014, 8(6): 618-629.
[17] KIM S M, LEE B, AN H J, et al. Novel PPARalpha agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging[J]. Oncotarget, 2017, 8(28): 46273-46285.
[18] EVANS R M, BARISH G D, WANG Y X. PPARs and the complex journey to obesity[J]. Nat Med, 2004, 10(4): 355-361.
[19] ZHAO N J, LIAO M J, WU J J, et al. Curcumin suppresses Notch1 signaling: Improvements in fatty liver and insulin resistance in rats[J]. Mol Med Rep, 2018, 17(1): 819-826.
[20] STANDAGE S W, BENNION B G, KNOWLES T O, et al. PPARalpha augments heart function and cardiac fatty acid oxidation in early experimental polymicrobial sepsis[J]. Am J Physiol Heart Circ Physiol, 2017, 312(2): H239-H249.
[21] KIM H, HALUZIK M, ASGHAR Z, et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis[J]. Diabetes, 2003, 52(7): 1770-1778.
[22] CHOU C J, HALUZIK M, GREGORY C, et al. WY14, 643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice[J]. J Biol Chem, 2002, 277(27): 24484-24489.